Published in Medicine and Law Weekly, March 18th, 2005
Data from the second patient cohort of the current phase 2a trial has further demonstrated that BrachySil (32-P BioSilicon) is safe and effective in tumor regression with increased efficacy.
Results of the second group of 4 patients, 12 weeks after their BrachySil treatment, revealed an average tumor regression by volume of 80% as determined by CT scanning. In some smaller tumors 100% regression was observed, a level of performance not seen with other intratumoral approaches. The study also...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.